Literature DB >> 23222368

Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States.

Megan E Daly1, Julian R Perks, Allen M Chen.   

Abstract

INTRODUCTION: Radiation oncologists were surveyed to assess practice patterns in the use of stereotactic body radiotherapy (SBRT) for lung cancer.
METHODS: A customized patterns-of-care survey, consisting of 18 questions and two clinical scenarios, was e-mailed to 136 academic radiation oncologists and 768 community practitioners to evaluate the technical basis and delivery parameters associated with SBRT.
RESULTS: A total of 117 surveys were evaluable. The cited delivery techniques included: static noncoplanar beams (48%), intensity-modulated radiotherapy (41%), rotational intensity-modulated radiotherapy (47%), dynamic conformal arcs (7%), and small-beam delivery with fiducial tracking (24%), with 46% using multiple techniques. The immobilization methods included: stereotactic frame (10%), alpha cradle or vacuum-lock system (52%), wingboard (3%), stereotactic frame with an alpha cradle or vacuum-lock system (11%); combination of devices (14%), or no immobilization (9%). Abdominal compression was used by 51% and respiratory gating by 31%. For a peripheral T1N0 tumor, the preferred doses included: 25 to 34 Gy in one fraction (1%); 54 to 60 Gy in three fractions (56%), 48 to 50 Gy in four fractions (18%), and 50 to 60 Gy in five fractions (25%). For a centrally located T1N0 tumor, 58% recommended SBRT outside a clinical protocol, with recommended doses ranging from 40 to 60 Gy in three to 10 fractions. The recommended interval to first surveillance imaging ranged from 6 weeks or lesser (32%) to 25 weeks or more (2%).
CONCLUSIONS: Considerable variation exists for thoracic SBRT with regard to dose selection, fractionation, immobilization, planning, management of central lesions, and surveillance. Ongoing prospective evaluation is recommended to identify best practices and provide continual process improvement.

Entities:  

Mesh:

Year:  2013        PMID: 23222368     DOI: 10.1097/JTO.0b013e318279155f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  20 in total

1.  Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Authors:  Katrina Woodford; Sashendra Senthi
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 2.  Alternatives to surgery in early stage disease-stereotactic body radiotherapy.

Authors:  Meredith Elana Giuliani; Andrea Bezjak
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium.

Authors:  G Distefano; A Baker; A J D Scott; G J Webster
Journal:  Br J Radiol       Date:  2014-03-13       Impact factor: 3.039

4.  One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.

Authors:  Anurag K Singh; Jorge A Gomez-Suescun; Kevin L Stephans; Jeffrey A Bogart; Gregory M Hermann; Lili Tian; Adrienne Groman; Gregory M Videtic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-08-22       Impact factor: 7.038

5.  Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer?

Authors:  Megan E Daly; Laurel A Beckett; Allen M Chen
Journal:  Pract Radiat Oncol       Date:  2013-10-08

Review 6.  Surveillance imaging following definitive radiotherapy for non-small cell lung cancer: What is the clinical impact?

Authors:  Brandon A Dyer; Megan E Daly
Journal:  Semin Oncol       Date:  2018-02-09       Impact factor: 4.929

7.  Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy.

Authors:  Sibo Tian; Jeffrey M Switchenko; Richard J Cassidy; Chase E Escott; Richard Castillo; Pretesh R Patel; Walter J Curran; Kristin A Higgins
Journal:  Transl Lung Cancer Res       Date:  2019-02

8.  A Survey of Stereotactic Body Radiotherapy in Korea.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo
Journal:  Cancer Res Treat       Date:  2014-11-24       Impact factor: 4.679

9.  Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.

Authors:  Joanne N Davis; Clinton Medbery; Sanjeev Sharma; John Pablo; Frank Kimsey; David Perry; Alexander Muacevic; Anand Mahadevan
Journal:  Radiat Oncol       Date:  2015-05-15       Impact factor: 3.481

10.  Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer.

Authors:  Seung-Gu Yeo; Eun Seog Kim
Journal:  Radiat Oncol J       Date:  2013-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.